Apyx Medical Co. (NASDAQ:APYX – Get Rating) was the recipient of a significant drop in short interest during the month of December. As of December 30th, there was short interest totalling 870,400 shares, a drop of 5.0% from the December 15th total of 916,400 shares. Currently, 2.9% of the company's shares are sold short. Based on an average daily trading volume, of 321,900 shares, the short-interest ratio is presently 2.7 days.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on APYX shares. JMP Securities cut Apyx Medical from an "outperform" rating to a "market perform" rating in a report on Thursday, November 10th. Piper Sandler cut their target price on Apyx Medical to $3.00 in a research note on Wednesday, November 16th. Craig Hallum cut their target price on Apyx Medical to $10.00 in a research note on Wednesday, November 16th. Finally, Lake Street Capital reaffirmed a "buy" rating and set a $5.00 price target on shares of Apyx Medical in a research report on Thursday, December 8th.

Apyx Medical Trading Up 1.5 %

APYX stock opened at $2.64 on Monday. The business's 50 day simple moving average is $2.06 and its 200 day simple moving average is $4.79. Apyx Medical has a 1-year low of $1.31 and a 1-year high of $12.16. The firm has a market capitalization of $91.34 million, a PE ratio of -4.71 and a beta of 1.20.

Institutional Trading of Apyx Medical

A number of hedge funds have recently modified their holdings of the stock. Taylor Frigon Capital Management LLC lifted its stake in shares of Apyx Medical by 0.6% during the 3rd quarter. Taylor Frigon Capital Management LLC now owns 497,314 shares of the company's stock worth $2,233,000 after buying an additional 3,136 shares during the last quarter. Rhumbline Advisers raised its stake in Apyx Medical by 16.1% in the 1st quarter. Rhumbline Advisers now owns 27,228 shares of the company's stock worth $178,000 after purchasing an additional 3,769 shares in the last quarter. Amalgamated Bank acquired a new stake in Apyx Medical in the 1st quarter worth about $33,000. Goldman Sachs Group Inc. raised its stake in Apyx Medical by 33.5% in the 2nd quarter. Goldman Sachs Group Inc. now owns 22,241 shares of the company's stock worth $130,000 after purchasing an additional 5,580 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its stake in Apyx Medical by 2.1% in the 1st quarter. Raymond James Financial Services Advisors Inc. now owns 302,606 shares of the company's stock worth $1,976,000 after purchasing an additional 6,150 shares in the last quarter. Institutional investors and hedge funds own 65.55% of the company's stock.

Apyx Medical Company Profile

(Get Rating)

Apyx Medical Corp. operates as an energy-based medical technology company. The firm engages in developing, manufacturing, and marketing a range of electrosurgical products and technologies, as well as related medical products used the offices of doctors, surgery centers, and hospitals worldwide. It operates through the following segments: Advanced Energy and Original Equipment Manufacture (OME).

Featured Stories

• Get a free copy of the StockNews.com research report on Apyx Medical (APYX)
• Chevron is Likely to Increase its Dividend Before Earnings
• MarketBeat Week in Review – 1/16 – 1/20
• Does Old Dominion Show That Trucking Is Hitting The Brakes?
• Nordstrom Puts Fear Of Markdowns Into Retail Sector
• Exxon Mobil Stock: Within Striking Distance Of Buy Point

Receive News & Ratings for Apyx Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apyx Medical and related companies with MarketBeat.com's FREE daily email newsletter.